Grifols (GRFS) Interest Expenses (2010 - 2018)
Grifols (GRFS) reported Interest Expenses of $85.1 million for Q2 2018, up 11.37% on a YoY basis from $76.4 million in Q2 2017, and up 25.7% quarter-over-quarter from $67.7 million in Q4 2017.
Grifols (GRFS) Interest Expenses (2010 - 2018) Analysis & Trends
Grifols has reported Interest Expenses for 8 years, with the latest figure at $85.1 million in Q2 2018.
- For the quarter ending Q2 2018, Interest Expenses rose 11.37% year-over-year to $85.1 million; the trailing twelve-month figure through Dec 2025 stood at -$0.0 (changed 0.0% YoY), and the FY2025 full-year result was $727.5 million, down 4.65% from the prior year.
- Interest Expenses for Q2 2018 stood at $85.1 million, up from $67.7 million in the prior quarter.
- The five-year high for Interest Expenses was $464.4 million in Q4 2016, with the low at -$69.7 million in Q1 2016.
- Historically, Interest Expenses has averaged $92.2 million across 4 years, with a median of $68.3 million in 2016.
- The largest YoY upside for Interest Expenses was 776.58% in 2016 against a maximum downside of 201.58% in 2016.
- Grifols' Interest Expenses stood at $53.0 million in 2015, then surged by 776.58% to $464.4 million in 2016, then slumped by 85.42% to $67.7 million in 2017, then rose by 25.7% to $85.1 million in 2018.
- The last three Interest Expenses figures came in at $85.1 million (Q2 2018), $67.7 million (Q4 2017), and $76.4 million (Q2 2017), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -225.15 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 272.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 657.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 240.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Grifols | 5.85 Bn | 4.89 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 85.10 Mn |
| Jun 30, 2018 | 85.10 Mn |
| Dec 31, 2017 | 67.70 Mn |
| Dec 31, 2017 | 67.70 Mn |
| Jun 30, 2017 | 76.41 Mn |
| Jun 30, 2017 | 76.41 Mn |
| Dec 31, 2016 | 464.37 Mn |
| Dec 31, 2016 | 464.37 Mn |
| Sep 30, 2016 | 68.29 Mn |
| Sep 30, 2016 | 68.29 Mn |
| Jun 30, 2016 | 68.74 Mn |
| Jun 30, 2016 | 68.74 Mn |
| Mar 31, 2016 | -69.74 Mn |
| Mar 31, 2016 | -69.74 Mn |
| Dec 31, 2015 | 52.98 Mn |
| Dec 31, 2015 | 52.98 Mn |
| Sep 30, 2015 | 67.25 Mn |
| Sep 30, 2015 | 67.25 Mn |
| Jun 30, 2015 | 64.73 Mn |
| Jun 30, 2015 | 64.73 Mn |